What is Exogenous HGH, sermorelin & older GHRPs (why they're passed over)?

Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library · Growth Hormone Secretagogues · Human Trials · What are peptides?

0 registered trials · 154 indexed papers · 1741 human / 853 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

Additional points (as described)

HGH enlarges existing cells rather than adding new ones; a constant level resembles a disease state. Reserved for acute repair phases or true deficiency.
Sermorelin lasts ~10–12 min before DPP-4 breaks it down.

Peer-reviewed studies (154)

Paper	Authors	Journal	Year	Type
Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure	Arimura H et al.	Endocrine journal	2016	Controlled Clinical Trial
Estradiol regulates GH-releasing peptide's interactions with GH-releasing hormone and somatostatin in postmenopausal women	Norman C et al.	European journal of endocrinology	2014	Randomized Controlled Trial
Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers	Cabrales A et al.	European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences	2013	Clinical Trial, Phase I
Gender, sex-steroid, and secretagogue-selective recovery from growth hormone-induced feedback in older women and men	Veldhuis JD et al.	The Journal of clinical endocrinology and metabolism	2011	Randomized Controlled Trial
Complex regulation of GH autofeedback under dual-peptide drive: studies under a pharmacological GH and sex steroid clamp	Veldhuis JD et al.	American journal of physiology. Endocrinology and metabolism	2011	Randomized Controlled Trial
Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment	Molica P et al.	Pituitary	2010	Clinical Trial
Secretagogue type, sex-steroid milieu, and abdominal visceral adiposity individually determine secretagogue-stimulated cortisol secretion	Iranmanesh A et al.	European journal of endocrinology	2010	Randomized Controlled Trial
Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus	de Sá LB et al.	Metabolism: clinical and experimental	2010	Randomized Controlled Trial
Diagnosis of adrenal insufficiency using the GHRP-6 Test: comparison with the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease	Alaioubi B et al.	Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme	2010	Clinical Trial
Pre- versus postmenopausal age, estradiol, and peptide-secretagogue type determine pulsatile growth hormone secretion in healthy women: studies using submaximal agonist drive and an estrogen clamp	Hudson SB et al.	The Journal of clinical endocrinology and metabolism	2010	Randomized Controlled Trial
Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6)	Correa-Silva SR et al.	Clinical endocrinology	2010	Randomized Controlled Trial
Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism	Veldhuis JD et al.	European journal of endocrinology	2009	Randomized Controlled Trial
Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis	Nascif SO et al.	Pituitary	2009	Controlled Clinical Trial
Factors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH agonist/testosterone clamp	Veldhuis JD et al.	The Journal of clinical endocrinology and metabolism	2009	Randomized Controlled Trial
Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies in men during experimental hypogonadal clamp	Veldhuis JD et al.	The Journal of clinical endocrinology and metabolism	2009	Randomized Controlled Trial
Determinants of GH-releasing hormone and GH-releasing peptide synergy in men	Veldhuis JD et al.	American journal of physiology. Endocrinology and metabolism	2009	Randomized Controlled Trial
Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men	Veldhuis JD et al.	European journal of endocrinology	2008	Controlled Clinical Trial
Gonadal status and body mass index jointly determine growth hormone (GH)-releasing hormone/GH-releasing peptide synergy in healthy men	Paulo RC et al.	The Journal of clinical endocrinology and metabolism	2008	Randomized Controlled Trial
Peripheral estrogen receptor-alpha selectively modulates the waveform of GH secretory bursts in healthy women	Veldhuis JD et al.	American journal of physiology. Regulatory, integrative and comparative physiology	2007	Randomized Controlled Trial
A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency	Chihara K et al.	European journal of endocrinology	2007	Controlled Clinical Trial
Estimation of the size and shape of GH secretory bursts in healthy women using a physiological estradiol clamp and variable-waveform deconvolution model	Veldhuis JD et al.	American journal of physiology. Regulatory, integrative and comparative physiology	2007	Randomized Controlled Trial
Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH	Nascif SO et al.	Pituitary	2007	Randomized Controlled Trial
Tripartite control of growth hormone secretion in women during controlled estradiol repletion	Veldhuis JD et al.	The Journal of clinical endocrinology and metabolism	2007	Clinical Trial
Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake	Laferrère B et al.	Obesity (Silver Spring, Md.)	2006	Randomized Controlled Trial
Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH	Correa-Silva SR et al.	Pituitary	2006	Controlled Clinical Trial
Testosterone supplementation in healthy older men drives GH and IGF-I secretion without potentiating peptidyl secretagogue efficacy	Veldhuis JD et al.	European journal of endocrinology	2005	Randomized Controlled Trial
Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects	Munafo A et al.	European journal of endocrinology	2005	Randomized Controlled Trial
Short-term testosterone supplementation does not activate GH and IGF-I production in postmenopausal women	Soares-Welch C et al.	Clinical endocrinology	2005	Randomized Controlled Trial
Joint mechanisms of impaired growth-hormone pulse renewal in aging men	Veldhuis JD et al.	The Journal of clinical endocrinology and metabolism	2005	Randomized Controlled Trial
Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep	Jessup SK et al.	European journal of endocrinology	2004	Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Exogenous HGH, sermorelin & older GHRPs (why they're passed over)?

Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

How many registered human trials study Exogenous HGH, sermorelin & older GHRPs (why they're passed over)?

The PeptideWhiz trial index lists 0 registered trials for Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

How much published research exists on Exogenous HGH, sermorelin & older GHRPs (why they're passed over)?

The PeptideWhiz paper index links 154 PubMed papers to Exogenous HGH, sermorelin & older GHRPs (why they're passed over); by study type, 1741 human and 853 animal studies.

Which conditions is Exogenous HGH, sermorelin & older GHRPs (why they're passed over) researched for?

Fat loss, obesity & body recomposition, Multiple sclerosis, Muscle gain, sarcopenia & building muscle after 40, Anti-aging & longevity, Atherosclerosis, cardiovascular disease & high blood pressure, Heart repair: after heart attack, heart failure & enlarged heart, Insulin resistance, prediabetes & type 2 diabetes, Low testosterone (without or alongside TRT), Post-surgical inflammation and surgery recovery, Sleep problems (incl. insomnia on peptides), Thyroid problems.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).